AnaBio is part of the Teagasc Moorepark Food Research Centre in Cork in southern Ireland and says its patented technology can boost oral delivery of peptides.
AnaBio said its method promoted the release of ‘satiety hormones’ and signaling peptides like glucagon-like peptide (GLP-1) and cholecystokinin (CCK) in the gut.
It said the technology could also deliver peptides to specific gut targets.
“Hence, this encapsulation system provides a novel dietary tool to control appetite and food intake,” it said.
Research shows that GLP-1 and CCK delay gastric emptying and promote a feeling of satiety.
“As a result, methods of enhancing GLP-1 secretion and oral peptide delivery has gained credibility from food formulators for the treatment of obesity and type-II diabetes. However, several major obstacles hinder oral peptide delivery as it is sensitive to stomach acid and enzymes.”
“So GLP-1 requires added protection to succeed as a credible treatment for type-II diabetes or obesity.”
The encapsulation method offered potential to allow GLP-1 to be, “administered in low doses, earlier and more efficiently in the progression of obesity and type II diabetes, which potentially broadens the market.”
“The technology also generates capsules with a muco-adhesive surface to enable prolonged hormone secretion and peptide residence time at the systemic target site.”